Orexigen Therapeutics Company Profile (NASDAQ:OREX)

About Orexigen Therapeutics

Orexigen Therapeutics logoOrexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: OREX
  • CUSIP: 68616410
Key Metrics:
  • Previous Close: $3.85
  • 50 Day Moving Average: $3.87
  • 200 Day Moving Average: $5.79
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.81
  • P/E Growth: 0.01
  • Market Cap: $56.16M
  • Outstanding Shares: 14,586,000
  • Beta: 2.03
Additional Links:
Companies Related to Orexigen Therapeutics:

Analyst Ratings

Consensus Ratings for Orexigen Therapeutics (NASDAQ:OREX) (?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings
Consensus Rating:Hold (Score: 1.88)
Consensus Price Target: $1.60 (58.44% downside)

Analysts' Ratings History for Orexigen Therapeutics (NASDAQ:OREX)
Show:
DateFirmActionRatingPrice TargetDetails
3/16/2016Leerink SwannLower Price TargetMarket Perform$2.00 -> $1.00View Rating Details
3/16/2016Piper Jaffray Cos.DowngradeOverweight -> Neutral$5.00 -> $2.00View Rating Details
3/16/2016JMP SecuritiesDowngradeOutperform -> Market PerformView Rating Details
2/29/2016JPMorgan Chase & Co.DowngradeOverweight -> NeutralView Rating Details
2/29/2016Royal Bank Of CanadaDowngradeOutperform -> Sector Perform$5.00 -> $1.00View Rating Details
12/16/2015WallachBeth CapitalDowngradeBuy -> HoldView Rating Details
12/12/2015Bank of America Corp.Reiterated RatingSellView Rating Details
12/4/2015Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details
9/4/2014Credit Suisse Group AGInitiated CoverageOutperform$10.00View Rating Details
(Data available from 8/26/2014 forward)

Earnings

Earnings History for Orexigen Therapeutics (NASDAQ:OREX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/3/2016        
8/4/2016Q216($1.47)($1.73)$6.88 million$7.79 millionViewListenView Earnings Details
5/4/2016Q116($0.17)($0.15)$7.78 million$5.00 millionViewListenView Earnings Details
2/26/2016Q415($0.08)($0.12)$14.07 million$4.90 millionViewListenView Earnings Details
11/5/2015Q315($0.16)($0.09)$12.17 million$10.00 millionViewListenView Earnings Details
8/6/2015Q215($0.17)($0.18)$4.92 million$5.20 millionViewListenView Earnings Details
5/8/2015Q115($0.16)($0.14)$7.28 million$4.36 millionViewListenView Earnings Details
11/10/2014Q3($0.13)$0.09$8.93 million$30.90 millionViewListenView Earnings Details
8/7/2014Q2($0.21)($0.21)$1.00 millionViewListenView Earnings Details
5/8/2014Q1($0.20)($0.23)ViewListenView Earnings Details
3/12/2014Q4($0.19)($0.21)$900.00 million$857.00 millionViewListenView Earnings Details
11/12/2013Q3($0.18)($0.19)$0.80 million$0.86 millionViewListenView Earnings Details
8/6/2013Q2 2013($0.19)($0.19)$0.90 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.44)($0.41)$0.91 million$0.86 millionViewListenView Earnings Details
11/7/2012Q312($0.30)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Orexigen Therapeutics (NASDAQ:OREX)
Current Year EPS Consensus Estimate: $-6.38 EPS
Next Year EPS Consensus Estimate: $-4.77 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.09)($0.09)($0.09)
Q2 20162($0.14)($0.10)($0.12)
Q3 20162($0.18)($0.10)($0.14)
Q4 20162($0.15)($0.11)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Orexigen Therapeutics (NASDAQ:OREX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Orexigen Therapeutics (NASDAQ:OREX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/2/2014Heather D TurnerSVPSell22,643$6.00$135,858.00View SEC Filing  
11/25/2014Heather D TurnerSVPSell31,388$5.83$182,992.04View SEC Filing  
11/18/2014Louis C BockDirectorBuy1,325$5.58$7,393.50View SEC Filing  
11/12/2014Louis C BockDirectorBuy27,052$5.57$150,679.64View SEC Filing  
9/22/2014Heather D TurnerVPSell300,000$4.47$1,341,000.00View SEC Filing  
9/15/2014Joseph P HaganVPBuy5,000$4.69$23,450.00View SEC Filing  
9/15/2014Michael NarachiCEOBuy50,000$4.78$239,000.00View SEC Filing  
7/31/2013Joseph P HaganInsiderSell12,000$7.80$93,600.00View SEC Filing  
7/26/2013Joseph P HaganInsiderSell10,000$7.40$74,000.00View SEC Filing  
7/25/2013Preston KlassenSVPSell71,229$7.16$509,999.64View SEC Filing  
5/28/2013Joseph P HaganInsiderSell28,000$7.00$196,000.00View SEC Filing  
5/28/2013Preston KlassenSVPSell28,771$7.21$207,438.91View SEC Filing  
1/15/2013Mark D BoothInsiderSell22,315$6.67$148,841.05View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Orexigen Therapeutics (NASDAQ:OREX)
DateHeadline
investornewswire.com logoOrexigen Therapeutics, Inc. (NASDAQ:OREX) Gets 1 Recommendations To Sell - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - August 22 at 6:40 PM
investing.com logoOrexigen Therapeutics: In Control Of Its Own Destiny (NASDAQ:OREX)
www.investing.com - August 19 at 6:36 PM
investornewswire.com logoWill Orexigen Therapeutics, Inc. (NASDAQ:OREX) Hit $5 Price Target? - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - August 16 at 9:56 AM
capitalcube.com logoETF’s with exposure to Orexigen Therapeutics, Inc. : August 15, 2016 (NASDAQ:OREX)
www.capitalcube.com - August 15 at 6:59 PM
finance.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Financials (NASDAQ:OREX)
finance.yahoo.com - August 13 at 6:20 PM
capitalcube.com logoOrexigen Therapeutics, Inc. :OREX-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:OREX)
www.capitalcube.com - August 12 at 6:48 PM
investornewswire.com logoWill Orexigen Therapeutics, Inc. (NASDAQ:OREX) Surprise This ... - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - August 8 at 6:55 PM
News IconOrexigen Reports Q2 Results (NASDAQ:OREX)
www.sdbj.com - August 7 at 6:20 PM
equities.com logoOrexigen Therapeutics Inc. (OREX) Jumps 6.84% on August 05 - Equities.com (NASDAQ:OREX)
www.equities.com - August 6 at 9:29 AM
News IconOrexigen Therapeutics Inc. (OREX) reports second-quarter earnings - BNB Daily (blog) (NASDAQ:OREX)
www.baseball-news-blog.com - August 6 at 9:29 AM
News IconOrexigen Reports Second Quarter Results (NASDAQ:OREX)
www.sdbj.com - August 5 at 6:52 PM
biz.yahoo.com logoOREXIGEN THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:OREX)
biz.yahoo.com - August 5 at 6:52 PM
finance.yahoo.com logoOrexigen Therapeutics Reports Business and Financial Results for the Second Quarter Ended June 30, 2 … (NASDAQ:OREX)
finance.yahoo.com - August 4 at 7:06 PM
sg.finance.yahoo.com logoOrexigen reports 2Q loss (NASDAQ:OREX)
sg.finance.yahoo.com - August 4 at 7:06 PM
News IconThe Pros and Cons of Clinical Trial Data Sharing (NASDAQ:OREX)
www.medscape.com - August 4 at 9:52 AM
biz.yahoo.com logoOrexigen Therapeutics Inc Earnings Call (Q2 2016) (NASDAQ:OREX)
biz.yahoo.com - August 4 at 9:52 AM
biz.yahoo.com logoQ2 2016 Orexigen Therapeutics Inc Earnings Release - After Market Close (NASDAQ:OREX)
biz.yahoo.com - August 4 at 9:52 AM
News IconThe Potential Dark Side of Data Sharing (NASDAQ:OREX)
www.medscape.com - August 3 at 7:03 PM
reuters.com logoBRIEF-Orexigen Therapeutics unit, ROVI announce agreement - Reuters (NASDAQ:OREX)
www.reuters.com - August 2 at 11:38 AM
streetinsider.com logoOrexigen Therapeutics (OREX) Enters Mysimba Distribution Agreement with ROVI - StreetInsider.com (NASDAQ:OREX)
www.streetinsider.com - August 2 at 11:38 AM
streetinsider.com logoOrexigen Therapeutics (OREX) to Pay Takeda $15M in January as Part of Separation Agreement (NASDAQ:OREX)
www.streetinsider.com - August 1 at 11:20 AM
reuters.com logoBRIEF-Orexigen Therapeutics unit, ROVI announce agreement (NASDAQ:OREX)
www.reuters.com - August 1 at 11:20 AM
finance.yahoo.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmacéuticos … (NASDAQ:OREX)
finance.yahoo.com - August 1 at 11:20 AM
twst.com logoOrexigen Therapeutics Inc.: Orexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization (NASDAQ:OREX)
www.twst.com - August 1 at 11:20 AM
prnewswire.com logoOrexigen Therapeutics Announces Commercialization and Distributorship ... (NASDAQ:OREX)
www.prnewswire.com - August 1 at 11:20 AM
publicnow.com logoOrexigen Completes Acquisition of All U.S. Rights to Contrave® and Launches U.S. Sales Organization (NASDAQ:OREX)
www.publicnow.com - August 1 at 8:41 AM
publicnow.com logoOrexigen Therapeutics Announces Commercialization and Distributorship Agreement with Laboratorios Farmacéuticos Rovi, S.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Spain (NASDAQ:OREX)
www.publicnow.com - August 1 at 8:41 AM
capitalcube.com logoETF’s with exposure to Orexigen Therapeutics, Inc. : July 29, 2016 (NASDAQ:OREX)
www.capitalcube.com - July 29 at 1:45 PM
kcregister.com logoBioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) soared 13.67%: Orexigen Therapeutics, Inc. (NASDAQ:OREX), DCT ... - KC Register (NASDAQ:OREX)
www.kcregister.com - July 28 at 6:54 PM
equities.com logoOrexigen Therapeutics Inc. (OREX) Jumps 7.03% on July 27 - Equities.com (NASDAQ:OREX)
www.equities.com - July 28 at 6:54 PM
investornewswire.com logoCan Shares Of Orexigen Therapeutics, Inc. (NASDAQ:OREX) Hit $6? - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - July 26 at 6:59 PM
equities.com logoOrexigen Therapeutics Inc. (OREX) Hits New 52-week Low During ... - Equities.com (NASDAQ:OREX)
www.equities.com - July 22 at 6:32 PM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on … (NASDAQ:OREX)
finance.yahoo.com - July 22 at 9:37 AM
finance.yahoo.com logoOrexigen Therapeutics to Provide Business Update and Discuss Second Quarter 2016 Financial Results on August 4, 2016 (NASDAQ:OREX)
finance.yahoo.com - July 21 at 4:10 PM
News IconOrexigen Therapeutics, Inc. (NASDAQ:OREX): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily (NASDAQ:OREX)
www.engelwooddaily.com - July 21 at 9:33 AM
News IconStock Moving Lower for the Month; Investor Update on Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Engelwood Daily (NASDAQ:OREX)
www.engelwooddaily.com - July 21 at 9:33 AM
fiscalstandard.com logoOrexigen Therapeutics, Inc. (NASDAQ:OREX) Current Analyst Ratings - Fiscal Standard (NASDAQ:OREX)
www.fiscalstandard.com - July 21 at 9:33 AM
news.cmlviz.com logoOrexigen Therapeutics, Inc. (NASDAQ:OREX) Fundamental Star Rating Report - CML News (NASDAQ:OREX)
news.cmlviz.com - July 21 at 9:33 AM
reuters.com logoZafgen to scrap lead obesity drug, shares slide (NASDAQ:OREX)
www.reuters.com - July 19 at 6:49 PM
capitalcube.com logoETF’s with exposure to Orexigen Therapeutics, Inc. : July 19, 2016 (NASDAQ:OREX)
www.capitalcube.com - July 19 at 12:57 PM
investornewswire.com logoIs $6 Price Target Attainable For Orexigen Therapeutics, Inc. (NASDAQ:OREX)? - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - July 19 at 7:52 AM
News IconOrexigen Therapeutics, Inc Has Another Bullish Trade, Biotechnology Value Fund L P Bought Stake! - Consumer Eagle (NASDAQ:OREX)
www.consumereagle.com - July 19 at 7:52 AM
News IconAre Analysts Bearish Orexigen Therapeutics, Inc. (NASDAQ:OREX) After Last Week? - Consumer Eagle (NASDAQ:OREX)
www.consumereagle.com - July 18 at 12:05 PM
News IconOrexigen Therapeutics, Inc. (NASDAQ:OREX) Wall Street Analyst Recommendation Outlook - TGP (NASDAQ:OREX)
telanaganapress.com - July 18 at 12:05 PM
News IconShares Experiencing a Downtrend: Orexigen Therapeutics, Inc. (NASDAQ:OREX) - TGP (NASDAQ:OREX)
telanaganapress.com - July 16 at 9:57 AM
streetupdates.com logoAnalyst's Overview of Two Stocks: Shire plc (NASDAQ:SHPG) , Orexigen Therapeutics, Inc. (NASDAQ:OREX) - Street Updates (NASDAQ:OREX)
www.streetupdates.com - July 13 at 7:01 PM
News IconOrexigen Therapeutics, Inc. (NASDAQ:OREX) Earnings Concentration and Analyst Target Watch - Engelwood Daily (NASDAQ:OREX)
www.engelwooddaily.com - July 13 at 7:01 PM
equities.com logoOrexigen Therapeutics Inc. (OREX) Drops 10.11% on July 11 - Equities.com (NASDAQ:OREX)
www.equities.com - July 13 at 9:36 AM
News IconCompany Shares of Orexigen Therapeutics (NASDAQ:OREX) Drops by -0.8% - TheFounders Daily (NASDAQ:OREX)
www.thefoundersdaily.com - July 12 at 6:55 PM
investornewswire.com logoStrong Sell Calls For Orexigen Therapeutics, Inc. (NASDAQ:OREX) At 0 - Investor Newswire (NASDAQ:OREX)
www.investornewswire.com - July 12 at 6:55 PM

Social

Orexigen Therapeutics (NASDAQ:OREX) Chart for Friday, August, 26, 2016


Last Updated on 8/26/2016 by MarketBeat.com Staff